Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04362865 · ClinicalTrials.gov registry record

Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
679
Enrollment target

NCT04362865: Completed study, sponsored by National Cancer Institute (NCI).

NCT04362865 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 679 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04362865 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
679 participants
Enrollment target

Study Summary

Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T cells are the major components of a person s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful. Objective: To examine how immune cells respond to COVID-19 infection. Eligibility: Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past. Also, healthy donors with no suspected COVID-19 infection Design: Participants will be screened with medical record review. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients. Participants with active infection must be isolated, usually in a hospital. Other participants may give blood samples at NIH or at their local doctor s office or lab. Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial. Participants will be contacted by phone or email every 2 months for up to 2 years.

Trial Details

FieldValue
Enrollment Target 679 participants
Start Date 2020-04-27
Est. Completion 2025-02-10

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT04362865

The ClinicalTrials.gov registry entry for NCT04362865 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 679 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04362865 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04362865 about?

NCT04362865 is a clinical study titled "Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection". Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T ce...

What is the current status of trial NCT04362865?

This trial is currently completed. The enrollment target is 679 participants. The study started on 2020-04-27. Estimated completion is 2025-02-10.

Who is sponsoring clinical trial NCT04362865?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.